Divi's Labs Q2 Preview: Earnings likely to improve sequentia

Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix

A high base from the sales of COVID drug Molnupiravir and soft demand is likely to weigh the year-on-year growth for Divi's Labs

Related Keywords

Prabhudas Lilladher , , Nuvama Institutional Equities , Kotak Institutional Equities , Incred Equities , Active Pharmaceutical Ingredients , Results , Divis Laboratories , Ivis Labs Q2 , Ivis Labs Q2 Results , Divis Labs Q2 Preview , Divis Labs Q2 Earnings , Ivis Labs Q2 Earnings Updates , Ivis Labs Q2 Results Updates ,